That’s a very good question. I’ve worked on it in the lab for two years. And for now, I think it’s still a myth. We have some data showing that ARPI in mCRPC is increasing PSMA, but it doesn’t mean that it’s associated with response to lutetium PSMA. And so my question is, maybe it’s just an artifact, an artificial increase, but it doesn’t mean that it’s associated with response to lutetium PSMA...
That’s a very good question. I’ve worked on it in the lab for two years. And for now, I think it’s still a myth. We have some data showing that ARPI in mCRPC is increasing PSMA, but it doesn’t mean that it’s associated with response to lutetium PSMA. And so my question is, maybe it’s just an artifact, an artificial increase, but it doesn’t mean that it’s associated with response to lutetium PSMA. The question is also, we are putting lutetium PSMA in mCRPC on hormone-sensitive setting and the PSMA upregulation is quite different. So from the PSMA upregulation point of view, I don’t think the current data we have is building on that, on this combination. But the AR is helping to respond, the AR inhibition is helping to respond and to increase response to radiation. And we know in localized prostate cancer that there is a synergy between androgen targeting and radiation so probably there is something not about the PSMA regulation but about the biology and the DNA damage that’s induced by lutetium PSMA.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
